Abrilada (adalimumab-afzb) NDC 0025-0325

NDC codes

FDA NDC Directory

Product NDC (as listed)0025-0325Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00025-0325Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0025-0325-01	00025032501	1 KIT in 1 CARTON (0025-0325-01) / 1 KIT in 1 KIT * .8 mL in 1 SYRINGE (0025-0318-01) * 1 mL in 1 PACKET (0069-1111-01)Marketed from Dec 14, 2023
0025-0325-02	00025032502	2 KIT in 1 CARTON (0025-0325-02) / 1 KIT in 1 KIT * .8 mL in 1 SYRINGE (0025-0318-01) * 1 mL in 1 PACKET (0069-1111-01)Marketed from Dec 14, 2023

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Abrilada
Generic name (nonproprietary): adalimumab-afzb
Dosage form: Kit
Labeler: Pfizer Laboratories Div Pfizer Inc
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761118
Marketing start: Dec 14, 2023
Listing expires: Dec 31, 2027
Identifiers: Product ID 0025-0325_0989d777-c225-46a6-854e-01bdf4f19679SPL ID 0989d777-c225-46a6-854e-01bdf4f19679SPL set ID 5ef1c7cf-466f-495e-8d13-82e2ddfa7a4fRxCUI 797544, 2668064, 2668071, 2668074, 2668078, 2668095, 2668096, 2668105, 2668106, 2668109, 2668113

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400025032501 followed by a unit qualifier and the quantity

Package 00025-0325-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) • Reducing signs and symptoms in adult patients with active ankylosing spondylit…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761118

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761118
Product	Strength	Form · route	Labeler	Product NDC
Abriladaadalimumab-afzb	—	Kit	Pfizer Laboratories Div Pfizer Inc	0025-0333
Abriladaadalimumab-afzb	—	Kit	A-S Medication Solutions	50090-7998
Abriladaadalimumab-afzb	—	Kit	A-S Medication Solutions	50090-8032
Abriladaadalimumab-afzb	—	Kit	Pfizer Laboratories Div Pfizer Inc	0025-0328